Severity of Nonalcoholic Fatty Liver Disease is Associated with Development of Metabolic Syndrome: Results of a 5-Year Cohort Study

Chung GE1, Yim JY1*, Kim D1, Park MJ1, Lim SH1, Yang JH1, Kim YS1, Yang SY1, Kwak MS1, Kim JS2, Cho SH1, Yoon JH2, Lee HS2

1Department of Internal Medicine, Healthcare Research Institute, Gangnam Healthcare Center, Seoul National University Hospital, Seoul, Korea. 2Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine Seoul, Korea.

Abstract

Aims: Nonalcoholic fatty liver disease (NAFLD) is considered to be a hepatic manifestation of metabolic syndrome (MS). However, a few studies have examined the effect of NAFLD on the development of MS. We evaluated the relationship between the development of MS and clinical severity of NAFLD according to alanine aminotransferase (ALT) levels.

Methods: A retrospective cohort study was conducted. Participants who underwent abdominal ultrasonography and blood samplings for health check-ups both in 2005 and 2010 were recruited. NAFLD was diagnosed if a person showed fatty liver on ultrasonography without significant alcohol consumption. Subjects with MS at baseline were excluded.

Results: A total of 2,728 subjects met the inclusion criteria. Fatty liver (FL) with normal ALT was found in 369 (13.5%) subjects and FL with elevated ALT in 328 (12.0%). During 5 years of follow up, 582 (21.3%) incident cases of MS developed between 2005 and 2010. The incidence of MS was higher in patients with NAFLD compared to control group (41.2% in FL with elevated ALT, 34.7% in FL with normal ALT and 15.7% in control, p<0.001). Multivariate analysis showed that odds ratio (OR) and 95% confidence interval (CI) for MS increased according to the severity of NAFLD [OR (95% CI), 1.29 (0.97–1.71) in FL with normal ALT and 1.54 (1.18–1.33) in FL with elevated ALT, p<0.01].

Conclusions: We have demonstrated that development of MS is significantly increased according to the clinical severity of NAFLD. These findings have implications in the clinical availability of NAFLD as a predictor of MS.

Keywords: Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease; Liver Enzyme.

Abbreviations: ALT: Alanine Aminotransferase; BMI: Body Mass Index; HDL: High Density Lipoprotein; FL: Fatty Liver; MS: Metabolic Syndrome; NAFLD: Non-Alcoholic Fatty Liver Disease.

*Corresponding Author: Jeong Yoon Yim, M.D., Ph.D., Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, 39FL, Gangnam Finance Center 737, Yeoksam-Dong, Gangnam-Gu, Seoul, 135-984, South Korea.
Tel: +82-02-2112-5784 Fax: +82-02-2112-5635 E-mail: yyy@snuh.org

Received: September 06, 2015 Accepted: September 26, 2015 Published: September 28, 2015

Citation: Yim JY et al., (2015) Severity of Nonalcoholic Fatty Liver Disease is Associated with Development of Metabolic Syndrome: Results of a 5-Year Cohort Study. Int J Diabetol Vasc Dis Res, 3(8) 122-126. doi: http://dx.doi.org/10.19070/2328-353X-1500025

Copyright: Yim JY © 2015. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is one of common causes of chronic liver disease, with increasing prevalence up to 20-30% worldwide [1]. NAFLD represents a group of conditions ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis [2]. Because the central pathogenesis of NAFLD is insulin resistance, NAFLD is considered to be a hepatic manifestation of metabolic syndrome (MS) [3]. In addition, NAFLD is closely linked to cardiovascular risk factors such as Type 2 diabetes, dyslipidemia and central obesity, which are components of metabolic syndrome [4, 5]. MS is related to atherosclerosis, cardiovascular disease, and as a result, increasing the development of diabetes and mortality of cardiovascular disease [6-8]. Many studies have shown the association between NAFLD and MS. A prospective observational study in Japan has identified MS as a strong predictor of NAFLD [9]. A recent study has found that the number of MS component was useful in predicting NAFLD [10]. However, a few studies have examined the effect of NAFLD the development of MS. Subjects with NAFLD and elevated liver enzyme was at an increased risk of developing MS [11]. A recent prospective cohort study showed that NAFLD was an independent risk factor for MS [12]. However, there is no data evaluating the development MS according to the severity of NAFLD including suspected simple steatosis and NASH based on general population. Therefore, the aim of this study was to determine the relationship between clinical severity of NAFLD according to ALT levels and the development of MS.
Patients and Methods

Study population

A retrospective cohort study was conducted to evaluate the association between NAFLD and the development of MS. The participants who underwent abdominal ultrasonography (US) and blood samplings at the Seoul National University Hospital Gangnam Healthcare Center, Seoul, Korea for routine health check-ups both in 2005 and 2010 were recruited. Most of the study population paid voluntarily for their health check-ups and some of them were supported by their company. 184 subjects positive for hepatitis B virus, 44 with positive hepatitis C virus, 754 subjects with alcohol consumption (>20 g/day for males and >10 g/day for females) and other hepatitis history were excluded. Among the 3,460 subjects enrolled, 732 subjects were excluded due to pre-existing MS. Finally, 2,728 subjects met inclusion criteria. This study was approved by the Institutional Review Board of the Seoul National University Hospital with a waiver of informed consent.

Clinical and laboratory assessments

Each subject completed a past medical history questionnaire and received an anthropometric assessment and laboratory and radiologic tests on the same day. Body weight and height were measured using a digital scale, and body mass index (BMI) was calculated by dividing weight (kg) by the square of height (m²). Waist circumference was measured at the midpoint between the lower costal margin and the anterior superior iliac crest by a well-trained person using a tape. Systolic blood pressure and diastolic blood pressure were measured twice, and the mean values were reported. The laboratory tests included serum alanine aminotransferase (ALT), total cholesterol, triglyceride, high density lipoprotein (HDL) cholesterol, fasting glucose, hepatitis B surface antigen and antibody to hepatitis C virus. Blood samples were collected before 10:00 AM after a 12-h overnight fast. All laboratory tests were carried out using standard laboratory methods.

Definitions

The presence of diabetes mellitus was defined as either a fasting serum glucose ≥126 mg/dL or use of anti-diabetic medication. The presence of hypertension was defined as having a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of anti-hypertensive medication. Current smokers were defined as having smoked at least 1 cigarette/day during the previous year. Former smokers were defined as prior regular cigarettes smoking. Abnormal liver enzyme values were based on ALT elevation over the strict cut-off point based on the updated definitions by Prati et al. 30 IU/L for men and 19 IU/L for women.

NAFLD was defined as the presence of fatty liver disease as determined by ultrasonography in the absence of the following: 1) seropositivity for hepatitis B surface antigen or antibody to hepatitis C virus, 2) excessive alcohol intake (>20 g/day for males and >10 g/day for females), 3) other causes of liver disease, and 4) medications known to produce fatty liver disease.

MS was diagnosed when three or more of the five components were present, that is, (1) central obesity [waist circumference as defined by the Regional Office for the Western Pacific Region of the World Health Organization (WPRO) criteria, >90 cm (men) or >80 cm (women)]; (2) a triglyceride level ≥150 mg/dL; (3) HDL-C <40 mg/dL (men) or <50 mg/dL (women); (4) fasting glucose ≥100 mg/dL or treatment for diabetes; (5) arterial pressure ≥130/85 mmHg or treatment for hypertension.

US assessments

US examination of the liver was performed by experienced radiologists who were unaware of the clinical information. The diagnosis of FL was performed by ultrasonography (Acuson, Sequioa 512, Siemens, Mountain View, CA) using previously described standardized criteria.

Statistical analysis

Comparisons of continuous variables between the two groups were performed with the Student’s t-test, and categorical variables were compared using the chi-square test or Fisher’s exact test. Variables that were statistically significant by univariate analysis and known risk factors were added to a multiple logistic regression model to identify independent predictors of the presence of NAFLD. Statistical analysis was performed with SPSS 19.0 (SPSS Inc.; Chicago, IL, USA). P-values <0.05 were considered statistically significant.

Results

Baseline characteristics

A total of 2,728 subjects were finally analyzed. Their mean age was 47.5 ± 9.7 years and 50.4% were male. The anthropometric, clinical and laboratory characteristics of the subjects are shown in Table 1. FL with normal ALT was found in 369 (13.5%) and FL with elevated ALT in 328 (12.0%) subjects at baseline. BMI, waist circumference, ALT, and triglyceride level were higher in patients with NAFLD compared to the control group (p<0.001).

Development of the metabolic syndrome

During 5 years of follow-up between 2005 and 2010, 582 (21.3%) incident cases of MS developed. The incidence of MS was higher in patients with NAFLD compared to control group (41.2% in FL with elevated ALT, 34.7% in FL with normal ALT and 15.7% in control, p<0.001). Subjects who developed MS on follow-up were older with greater central obesity, dyslipidemia, and blood pressure at the time of baseline assessment compared to those who did not develop MS (p<0.001, Table 2).

To examine incident MS according to the NAFLD categories (control, FL with normal ALT and FL with elevated ALT), analysis was stratified according to baseline NAFLD categories (Table 3). In age and sex adjusted model, odds ratio (OR) and 95% confidence (CI) interval for MS increased according to the degree of NAFLD [1.99 (1.54−2.59) in FL with normal ALT and 3.09 (2.38−4.01) in FL with elevated ALT, p<0.001]. These associations were attenuated, but still remained significant, even after further adjustments for covariates, such as BMI, smoking, central obesity, hypertension, glucose, triglyceride and high-density lipoprotein cholesterol (model 2). OR (95% CI), 1.29 (0.97−1.71) in FL with normal ALT and 1.54 (1.18−1.33) in FL with elevated ALT, p<0.01.
Table 1. Comparison of baseline characteristics in nonalcoholic fatty liver disease with or without elevated alanine aminotransferase versus control.

|                      | Control (n=2,031) | FL with normal ALT (n=369) | FL with elevated ALT (n=328) | p for trend |
|----------------------|-------------------|-----------------------------|-------------------------------|------------|
| Age, years           | 47.0 ± 9.7        | 49.8 ± 9.2                  | 48.1 ± 9.6                   | <0.001     |
| Male sex, %          | 843 (41.5)        | 292 (79.1)                  | 239 (72.9)                   | <0.001     |
| Smoking, %           | 252 (12.4)        | 74 (20.1)                   | 71 (21.6)                    | <0.001     |
| Body mass index, kg/m² | 21.9 ± 2.7       | 24.1 ± 2.1                  | 22.6 ± 2.9                   | <0.001     |
| Waist circumference, cm | 80.9 ± 8.0       | 85.6 ± 5.4                  | 87.2 ± 9.5                   | <0.001     |
| ALT, IU/L            | 19.8 ± 11.9       | 20.1 ± 5.6                  | 44.2 ± 23.0                  | <0.001     |
| Fasting glucose, mg/dL | 94.8 ± 11.3      | 102.2 ± 18.8                | 100.8 ± 15.8                 | <0.001     |
| Triglycerides, mg/dL | 83.5 ± 38.3       | 114.9 ± 51.7                | 120.5 ± 67.4                 | <0.001     |
| HDL cholesterol, mg/dL | 58.0 ± 13.2      | 51.0 ± 10.7                 | 50.9 ± 11.4                  | <0.001     |
| CRP, mg/dL           | 0.08 ± 0.21       | 0.09 ± 0.30                 | 0.09 ± 0.23                  | 0.316      |
| Hypertension, %      | 186 (9.6)         | 56 (15.2)                   | 50 (15.2)                    | <0.001     |
| 5-year metabolic syndrome development | 319 (15.7) | 128 (34.7) | 135 (41.2) | <0.001 |

Data are presented as the mean ± SD

P-value by ANOVA-test for continuous variables and Chi square test for categorical variables

ALT, alanine aminotransferase; CRP, C-reactive protein; FL, fatty liver; HDL, high density lipoprotein;

Table 2. Baseline characteristics associated with development of metabolic syndrome over 5-year follow up period.

|                      | MS absent at follow-up (n=2,146) | MS present at follow-up (n=582) | p    |
|----------------------|----------------------------------|--------------------------------|------|
| Age, years           | 46.5 ± 9.4                       | 51.3 ± 9.7                     | <0.001 |
| Male sex, %          | 959 (44.7)                       | 415 (71.3)                     | <0.001 |
| Smoking, %           | 273 (12.7)                       | 74 (20.1)                      | <0.001 |
| Body mass index, kg/m² | 22.1 ± 2.8          | 24.2 ± 2.7                     | <0.001 |
| Waist circumference, cm | 80.5 ± 7.9         | 86.1 ± 8.8                     | <0.001 |
| ALT, IU/L            | 21.5 ± 14.7                     | 27.2 ± 16.9                    | <0.001 |
| Fasting glucose, mg/dL | 94.8 ± 11.2        | 103.1 ± 18.3                   | <0.001 |
| Triglycerides, mg/dL | 87.4 ± 44.1                     | 109.6 ± 53.5                   | <0.001 |
| HDL-cholesterol, mg/dL | 57.0 ± 13.4       | 53.4 ± 11.1                    | <0.001 |
| Hypertension, %      | 141 (6.6)                       | 151 (25.9)                     | <0.001 |

MS, metabolic syndrome; ALT, alanine aminotransferase; HDL, high density lipoprotein

Table 3. Age- and sex-adjusted and multivariable analyses of risk of metabolic syndrome in nonalcoholic fatty liver disease with or without elevated ALT versus control.

|                      | Control (n=2,031) | FL with normal ALT (n=369) | FL with elevated ALT (n=328) | p for trend |
|----------------------|-------------------|-----------------------------|-------------------------------|------------|
| Subjects who developed MS, n (%) | 319 (15.7) | 128 (34.7) | 135 (41.2) | <0.001 |
| Adjusted OR (95% CI) Model 1 | 1 (reference) | 1.99 (1.54–2.59) | 3.09 (2.38–4.01) | <0.001 |
| Model 2,                         | 1 (reference) | 1.29 (0.97–1.71) | 1.54 (1.18–1.33) | <0.01 |

Model 1: adjusting for age and sex; Model 2: adjusting for age, sex, BMI, smoking, central obesity, hypertension, glucose, triglyceride and high-density lipoprotein. MS, metabolic syndrome; ALT, alanine aminotransferase; FL, fatty liver; OR, odds ratio; CI, confidence interval
We next investigated whether serum ALT threshold associated with the development of MS. Figure 1 illustrates that higher baseline ALT levels were significantly correlated with the development of MS in the subjects with NAFLD. Table 4 shows the effect sizes of NAFLD among groups divided according to each metabolic component for the development of MS. The effect of NASH on the development of MS was comparable to other components of MS except hypertension.

**Discussion**

The study showed that incidence of MS was increased in NAFLD patients according to the NAFLD categories (control, FL with normal ALT and FL with elevated ALT). These findings suggest an independent role of NAFLD in the development of MS. Consistent with our study, Adams et al. [11] reported that subjects with NAFLD and elevated ALT levels are at increased risk of developing MS. However, NAFLD was not a significant predictor of the development of MS in multivariate analysis in the study [11]. In addition, subjects with NAFLD and normal ALT levels were not included in the study, because definition of NAFLD was based only ALT levels. A case-control study [17] has shown that the presence of NAFLD may predict the development of metabolic disorders due to insulin resistance. However, the definition of metabolic disorders is not clear and there was no data about NASH [17]. A recent prospective cohort study showed that the risk of MS independently increased according to the degree of NAFLD [12]. In this study, the subjects were confined to male and the degree of NAFLD was categorized by only US. Most studies using US refer to a three-score system for FL (mild, moderate and severe) based on echogenity of the liver [18, 19]. Although US is an established tool as a screening modality with acceptable sensitivity and specificity in detecting FL, US has limitations in grading the severity of NAFLD [20]. First, because of operator-dependency of US imaging, it is inaccurate in the quantification of fat accumulation. A retrospective study showed that the mean intra-observer agreement for severity of FL ranged from 55% to 68% [21]. Second, it is difficult to distinguish simple steatosis from steatohepatitis or fibrosis [22] as these have similar sonographic findings.

The presence of NAFLD on sonographic finding does not always indicate elevated ALT level. Only 16.5% of women and 14.5% of men above the 75th percentiles of ALT (≥19 for women and ≥23 for men) showed sonography findings of NAFLD [23]. Wang et al. [24] showed that coexistence of NAFLD and elevated ALT (>30) were associated with insulin resistance in young Han males, providing evidence of a relationship between NAFLD and elevated ALT level. In this study, we stratified subjects with NAFLD according to the ALT levels; NAFLD with normal ALT vs. NAFLD with elevated ALT (>30), which may reflect the presence of NASH, and development of MS was significantly higher according to the degree of NAFLD. As a result, the odds ratio of NASH on the development of MS was comparable to other components of MS, which suggests the role of a NASH as one component of MS. Using similar criteria for NAFLD categories to our study, Sung et al. [25] have shown that overall cardiovascular risk was significantly greater in NASH, defined as steatosis and an increased serum ALT, than either simple steatosis or raised ALT alone. Baumeister et al. [26] have identified that subjects with so-

**Figure 1.** Cumulative probability for the development of metabolic syndrome in 5-year follow-up in subjects with nonalcoholic fatty liver disease according to baseline ALT levels.

**Table 4.** The effect size of nonalcoholic fatty liver disease and groups divided according to each metabolic component for the development of metabolic syndrome. (Age, sex, body mass index and smoking adjusted).

| Metabolic Component | OR (95% CI) |
|---------------------|-------------|
| Glucose > 100       | 2.00 (1.62−2.49) |
| Obesity             | 1.42 (1.08−1.88) |
| Hypertriglyceremia  | 1.55 (1.13−2.11) |
| Low HDL             | 1.82 (1.31−2.54) |
| Hypertension        | 3.01 (2.42−3.74) |
| FL with normal ALT  | 1.47 (1.12−1.93) |
| FL with elevated ALT| 1.84 (1.39−2.44) |

ALT, alanine aminotransferase; OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein; FL, fatty liver
nographic FL and increased serum ALT levels had higher overall health care cost at 5-year follow up. These findings suggest that NAFLD categories used in this study are useful for predicting the prognosis of NAFLD.

In our study, development of MS was increased according to the increased ALT levels in subjects with NAFLD. The findings are in accordance with the two previous studies [27,28]. An Australian population-based cohort study has found a strong association between ALT level and MS independent of insulin resistance [27]. Another study has suggested the role of ALT as an indicator for the 6-year risk of MS development in a general population of middle-aged Caucasians [28]. However, presence of NAFLD was not considered in these studies.

The strength of our study is that this is the first to determine the causal relationship between the severity of NAFLD and the development of MS providing substantial duration of follow-up. Moreover, the subjects in our study are representative of the general population due to the nature of a health check-up. Finally, the clinical diagnosis of NAFLD and suspected NASH used in this study may have implications for clinicians managing patients in the primary care center.

There are limitations of our study. First, hepatic sonography is used as a diagnostic tool for NAFLD, and this method cannot diagnose a small fatty infiltration below 30%. However, because of its relatively high sensitivity up to 84.8% and specificity up to 93.6%, hepatic ultrasound is widely used a diagnostic test for NAFLD. Although a biopsy was needed for grading for severity of NAFLD, we categorized NAFLD groups according to ALT levels. Actually, biopsies were not available in all subjects with NAFLD, and this grouping has been generally accepted. Second, there might be a selection bias, because this study was performed at a single health screening center and we did not evaluate whether the subjects were treated during the study period because of a retrospective design. Third, we cannot identify the effect of insulin resistance because there was no data regarding insulin levels in this study. However, a previous study in China established the association between NAFLD with elevated ALT with insulin resistance [24], supporting our results.

Conclusion

We have demonstrated that the development of MS is significantly increased according to the clinical severity of NAFLD during a 5-year follow-up. These findings have implications in the clinical availability of NAFLD as a predictor of MS.

References

[1]. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34(3): 274-285.
[2]. Clark JM (2006) The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40(Suppl 1): S5-10.
[3]. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8): 1844-1850.
[4]. Pagano G, Pacini G, Musso G, Gambino R, Meccia F, et al. (2002) Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35(2): 367-372.
[5]. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lencz M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4): 917-923.
[6]. Lakkal HM, Laaksonen DE, Lakka TA, Nikkanen JK, Kumpusalo E, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21): 2709-2716.
[7]. Hanson RL, Imperatore G, Bennett PH, Knowler WC (2002) Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51(10): 3120-3127.
[8]. Gami AS, Wirt BJ, Howard DE, Erwin PJ, Gami LA, et al. (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49(4): 403-414.
[9]. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, et al. (2010) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143(10): 722-728.
[10]. Wang Y, Li Y, Nie YQ, Zhou Y, Cao CY, et al. (2013) Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med 6(1): 77-84.
[11]. Adams LA, Waters OR, Knuijman MW, Elliott RR, Olynk JK (2009) NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104(4): 861-867.
[12]. Ryoo JH, Choi JM, Moon SY, Suh YJ, Shin JY, et al. (2013) The clinical availability of nonalcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year’s prospective cohort study. Atherosclerosis 227(3): 398-403.
[13]. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18): 1837-1847.
[14]. Prati D, Taidi E, Zanella A, Della Torre E, Burelli S, et al. (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137(1): 1-10.
[15]. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). (2001) JAMA 285(19): 2486-2497.
[16]. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, et al. (2009) The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 104(8): 1953-1960.
[17]. Fan JG, Li F, Cai XB, Peng YD, Ao QH, et al. (2007) Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hепatol 22(7): 1086-1091.
[18]. Saverymuttu SH, Joseph AE, Maxwell JD (1986) Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292(6512): 13-15.
[19]. Hamaguchi M, Kojima T, Inoh Y, Harano Y, Fujii K, et al. (2007) The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102(12): 2708-2715.
[20]. Schwenger NF, Springer F, Schraml C, Stefan N, Machann J, et al. (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51(3): 453-455.
[21]. Strauss S, Gavish E, Gottlieb F, Katznelson I (2007) Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 189(6): W320-323.
[22]. Clark JM, Brancati FL, Diehl AM (2007) Nonalcoholic fatty liver disease. Gastroenterology 132(6): 1649-1657.
[23]. Salazar MR, Carbañal HA, Cucurullero JO, Aispuruza M, Adrover RE, et al. (2007) Alanine-aminotransferase: an early marker for insulin resistance? Medicine (B Aires) 67(2): 125-130.
[24]. Wang R, Lu Q, Feng J, Yin F, Qin C, et al. (2012) Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine 41(1): 70-75.
[25]. Sung KC, Ryan MC, Wilson AM (2009) The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 203(2): 581-586.
[26]. Baumeister SE, Voldke H, Marschall P, John U, Schmidt CO, et al. (2008) Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 134(1): 85-94.
[27]. Olynk JK, Knuijman MW, Divitini ML, Davis TM, Beilby J, et al. (2009) Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 104(7): 1715-1722.
[28]. Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, et al. (2007) Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hordox Study. Diabet Med 24(4): 430-435.
[29]. Saadah S, Younossi ZM, Remer EM, Grishik LA, Ong JP, et al. (2002) The utility of radiologic imaging in nonalcoholic fatty liver disease. Gastroenterology 122(6): 1649-1657.
[30]. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, et al. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54(3): 1082-1090.